Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study
This real-world study demonstrated that most US patients with la/mUC received platinum-based chemotherapy or a PD-1/L1 inhibitor prior to EV therapy from 2015 to 2020. HRU and costs 12 months before EV initiation suggest a substantial burden in this population. Long-term studies with more recent data are warranted.
Authors
- Hongbo Yang (ORCID: https://orcid.org/0000-0003-2741-8418)
- Vanessa Shih (ORCID: https://orcid.org/0000-0002-2470-5932)
- Lisa Mucha
- Alexandra Greatsinger (ORCID: https://orcid.org/0000-0001-8576-8614)
- Alicia Katherine Morgans (ORCID: https://orcid.org/0000-0002-6563-4587)
- Angela Lax (ORCID: https://orcid.org/0000-0001-9577-8904)
- Bin Xie
- Christina Marie Quicquaro
- Qing Liu (ORCID: https://orcid.org/0000-0003-1357-4866)
- Christopher Young (ORCID: https://orcid.org/0000-0002-3812-7301)
Institutions
- Pfizer (United States) (US)
- Dana-Farber Cancer Institute (US)
- Astellas Pharma (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1111/iju.70023
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Seagen
- Astellas Pharma